We favour the former model, as the low detection level of a TSC2 mutation or evidence of mTOR dysregulation in cells derived from LAM lung argues against the presence of large numbers of clonally derived mutation-carrying LAM cells. The gene discussed is MTOR; the disease is lymphangioleiomyomatosis.